Xenetic Biosciences (STU:3XB0) Other Stockholders Equity: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:3XB0 Xenetic Biosciences Inc STU:3XB0
78 GF Score
Price €3.10
GF Value €4.66
! 2 Warning Signs
View Full Analysis

What is Xenetic Biosciences Other Stockholders Equity?

Xenetic Biosciences STU:3XB0 78 Other Stockholders Equity is €0.00 Mil as of Mar. 2026. GuruFocus rates STU:3XB0 with a GF Score™ of 78/100 and a GF Value™ of €4.66. The stock has 2 warning signs investors should review.

Xenetic Biosciences's Other Stockholders Equity for the quarter that ended in Mar. 2026 was €0.00 Mil.

Xenetic Biosciences's quarterly Other Stockholders Equity increased from Sep. 2025 (€-0.00 Mil) to Dec. 2025 (€-0.00 Mil) and increased from Dec. 2025 (€-0.00 Mil) to Mar. 2026 (€0.00 Mil).

Xenetic Biosciences's annual Other Stockholders Equity declined from Dec. 2023 (€-0.00 Mil) to Dec. 2024 (€-0.00 Mil) but then increased from Dec. 2024 (€-0.00 Mil) to Dec. 2025 (€-0.00 Mil).

Xenetic Biosciences Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Xenetic Biosciences's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xenetic Biosciences Other Stockholders Equity Chart

Xenetic Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 -0.00 -0.00 -0.00 -0.00

Xenetic Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 -0.00 -0.00 0.00
STU:3XB0
78GF Score
Xenetic Biosciences Inc STU:3XB0
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xenetic Biosciences Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €0.00 Mil mean?
Xenetic Biosciences (STU:3XB0) has a Other Stockholders Equity of €0.00 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Xenetic Biosciences and its competitors.
Is Xenetic Biosciences' Other Stockholders Equity too high?
Xenetic Biosciences' current Other Stockholders Equity is €0.00 Mil. Overall, Xenetic Biosciences has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Xenetic Biosciences' Other Stockholders Equity compare to ACXP and SILO?
Xenetic Biosciences' Other Stockholders Equity of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Xenetic Biosciences and its competitors. Xenetic Biosciences's current Other Stockholders Equity is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xenetic Biosciences stock overvalued right now?
Xenetic Biosciences (STU:3XB0) has a current Other Stockholders Equity of €0.00 Mil. The stock's GF Value™ is €4.66, compared to a current price of €3.10 — trading 33.5% below its estimated fair value. The current Other Stockholders Equity is €0.00 Mil. Xenetic Biosciences' overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Xenetic Biosciences (STU:3XB0), the current Other Stockholders Equity is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xenetic Biosciences (STU:3XB0) Overvalued in 2026?

Based on GuruFocus' analysis, Xenetic Biosciences stock appears to be undervalued. The current stock price of €3.10 is trading 33.5% below its estimated GF Value™ of €4.66.

Key valuation signals for STU:3XB0:

  • Other Stockholders Equity: €0.00 Mil
  • GF Value™: €4.66 vs. price of €3.10 (33.5% below fair value)
  • GF Score™: 78/100 with 2 warning signs

No single metric tells the full story. See the STU:3XB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xenetic Biosciences Business Description

Other Exchanges XBIO:USA
Address 945 Concord Street, Framingham, MA, USA, 01701
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
78GF Score

Get the complete analysis for STU:3XB0

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.10
Price
€4.66
GF Value